There is limited information on access and outcomes of patients living with human immunodeficiency virus (HIV) (PLWH) who have undergone pancreas transplantation. We conducted a retrospective cohort study analyzing data from the United Network for Organ Sharing from July 1, 2001, to June 30, 2021. Recipients of pancreas transplant were stratified by HIV serostatus. Graft and patient survival were analyzed using Kaplan-Meier product limit estimates. Multivariable Cox proportional hazard models were generated to identify factors associated with increased mortality or graft loss. Fifty PLWH and 16 380 patients without HIV underwent pancreas (with kidney) transplantation. PLWH were more often male (P < .001), Black/African American (P = .009), and on Medicare (P = .004). There were no significant differences in waiting time (P = .159) or proportion of patients treated for rejection within 1 year of transplant (P = .189) between groups. There were no differences in pancreas graft survival (P = .964) and overall patient survival (P = .250) between the cohorts. Dialysis status was negatively associated with graft survival. Although PLWH were more likely to represent a historically marginalized population, their outcomes after pancreas transplant were similar to their HIV-negative counterparts.

中文翻译：

---

人类免疫缺陷病毒感染患者的胰腺移植结局


关于接受胰腺移植的人类免疫缺陷病毒 （HIV） （PLWH） 患者的可及性和结局的信息有限。我们进行了一项回顾性队列研究，分析了 2001 年 7 月 1 日至 2021 年 6 月 30 日器官共享联合网络的数据。胰腺移植受者按 HIV 血清状态分层。使用 Kaplan-Meier 乘积限估计分析移植物和患者生存率。生成多变量 Cox 比例风险模型以确定与死亡率增加或移植物损失相关的因素。50 名 PLWH 患者和 16 380 名无 HIV 患者接受了胰腺（含肾脏）移植。PLWH 更常见的是男性 （P < .001）、黑人/非裔美国人 （P = .009） 和医疗保险 （P = .004）。两组之间等待时间 （P = .159） 或移植后 1 年内接受排斥反应治疗的患者比例 （P = .189） 无显著差异。队列之间的胰腺移植物生存率 （P = .964） 和总患者生存率 （P = .250） 没有差异。透析状态与移植物存活率呈负相关。尽管 PLWH 更有可能代表历史上被边缘化的人群，但他们在胰腺移植后的结果与 HIV 阴性的同类相似。